Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Computing & Software • Transportation, E-Commerce & Mechanical Systems
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Taipei Veterans General Hospital currently manages 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 6 distinct examiners, including SHIAO, YIH-HORNG, who is the busiest examiner with 1 pending action. The portfolio's pending matters are spread across 5 distinct art units. This high level of distribution indicates that the company's biotechnology applications are being evaluated across multiple specialized units.
Managing 6 pending office actions across 5 distinct art units requires a diversified prosecution strategy. Because there are 6 distinct examiners involved, the practitioner must account for a wide range of individual examiner preferences and art unit standards. SHIAO, YIH-HORNG handles 1 pending action, meaning no single examiner dominates the portfolio's current workload. This distribution across 5 art units suggests that the hospital's research spans several different sub-fields within the Biotechnology & Pharmaceuticals sector, each with its own unique examination challenges.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 2 (33%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, YIH-HORNG | 1 | 72.5% | +75.9% |
| PATEL, NEHA | 1 | 23.2% | +21.0% |
| KASAYAN, KATRIEL BARCELLANO | 1 | 25.0% | +0.0% |
| KONOPKA, CATHERINE ANNE | 1 | 58.1% | +65.0% |
| PARK, GRACE A | 1 | 76.3% | +17.6% |
| MCCORMICK, CATHERINE LYNN | 1 | 50.0% | +42.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18584818 | SYSTEM AND METHOD FOR MANAGING MEDICAL QUALITY INDICATOR | PATEL, NEHA | 13d |
| 18690712 | SYNTHETIC COMPOUND, KIT COMPRISING THE SAME, AND USES THEREOF | SHIAO, YIH-HORNG | — |
| 18407238 | SPECIMEN TREATMENT METHOD | KASAYAN, KATRIEL BARCELLANO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18584818 | SYSTEM AND METHOD FOR MANAGING MEDICAL QUALITY INDICATOR | PATEL, NEHA | 13d |
| 18690712 | SYNTHETIC COMPOUND, KIT COMPRISING THE SAME, AND USES THEREOF | SHIAO, YIH-HORNG | — |
| 18515028 | NANOPARTICLES-MEDIATED CRISPR-CAS9 FOR GENE THERAPY | KONOPKA, CATHERINE ANNE | — |
| 18308625 | LEFT VENTRICULAR HYPERTROPHY PREDICTION MODEL TRAINING METHOD AND DEVICE THEREOF | PARK, GRACE A | — |
| 17924933 | COMPOSITIONS AND METHODS FOR TREATING SLC26A4-ASSOCIATED HEARING LOSS | MCCORMICK, CATHERINE LYNN | — |
| Art Unit | Apps |
|---|---|
| 3699 | 1 |
| 1634 | 1 |
| 4100 | 1 |
| 2144 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18690712 | SYNTHETIC COMPOUND, KIT COMPRISING THE SAME, AND USES THEREOF | SHIAO, YIH-HORNG | — | §102§103§112 | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18584818 | SYSTEM AND METHOD FOR MANAGING MEDICAL QUALITY INDICATOR | PATEL, NEHA | 3699 | §101§102§103§112 | Non-Final OA | 13d | Pending | Feb 22, 2024 |
| 18407238 | SPECIMEN TREATMENT METHOD | KASAYAN, KATRIEL BARCELLANO | 1634 | §103§112 | Final Rejection | — | Pending | Jan 08, 2024 |
| 18515028 | NANOPARTICLES-MEDIATED CRISPR-CAS9 FOR GENE THERAPY | KONOPKA, CATHERINE ANNE | 4100 | §102§103§112DP | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18308625 | LEFT VENTRICULAR HYPERTROPHY PREDICTION MODEL TRAINING METHOD AND DEVICE THEREOF | PARK, GRACE A | 2144 | §103 | Final Rejection | — | Pending | Apr 27, 2023 |
| 17924933 | COMPOSITIONS AND METHODS FOR TREATING SLC26A4-ASSOCIATED HEARING LOSS | MCCORMICK, CATHERINE LYNN | 1638 | §103 | Non-Final OA | — | Pending | Nov 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial